Bendheim Daniel M 4
4 · PHIBRO ANIMAL HEALTH CORP · Filed Jan 30, 2019
Insider Transaction Report
Form 4
Bendheim Daniel M
DirectorExec. VP, Corporate Strategy
Transactions
- Sale
Class A Common Stock
2019-01-28$31.55/sh−2,500$78,875→ 0 total - Exercise/Conversion
Class A Common Stock
2019-01-28$11.83/sh+2,500$29,575→ 2,500 total - Exercise/Conversion
Class A Common Stock
2019-01-29$11.83/sh+4,890$57,849→ 4,890 total - Sale
Class A Common Stock
2019-01-29$31.32/sh−4,890$153,155→ 0 total - Exercise/Conversion
Class A Common Stock
2019-01-30$11.83/sh+2,390$28,274→ 2,390 total - Sale
Class A Common Stock
2019-01-30$31.15/sh−2,390$74,449→ 0 total - Exercise/Conversion
Option to purchase Common Stock
2019-01-28−2,500→ 7,280 totalExercise: $11.83From: 2013-03-01Exp: 2019-02-28→ Class A Common Stock (2,500 underlying) - Exercise/Conversion
Option to purchase Common Stock
2019-01-29−4,890→ 2,390 totalExercise: $11.83From: 2013-03-01Exp: 2019-02-28→ Class A Common Stock (4,890 underlying) - Exercise/Conversion
Option to purchase Common Stock
2019-01-30−2,390→ 0 totalExercise: $11.83From: 2014-03-01Exp: 2019-02-28→ Class A Common Stock (2,390 underlying)
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2018, as amended on September 12, 2018.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.19 to $32.08, inclusive.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.08 to $31.73, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.04 to $31.30, inclusive.